Daclatasvir Dihydrochloride CAS 1009119-65-6 Munditia >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae Daclatasvir Dihydrochloridis (CAS: 1009119-65-6) qualitatis princeps.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Daclatasvir Dihydrochloride,Please contact: alvin@ruifuchem.com
| Nomen chemicum | Daclatasvir Dihydrochloride |
| Synonyma | Daclatasvir DiHCl;BMS-790052 Dihydrochloride;BMS 790052 (Di HCl Salt);EBP 883 Dihydrochloride;N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-Imidazole-5,2-diyl-(2S)-2,1-Pyrrolidinediyl[(1S)-1-(1 -Methylethyl)-2-oxo-2,1-Ethanediyl]]] Acidum biscarbamicum Dimethyl Ester Hydrochloridum |
| Stock Status | In Stock, 300/Kilograms per Month |
| CAS Number | 1009119-65-6 |
| Formulae hypotheticae | C40H51ClN8O6 |
| M. Pondus | 775.35 g/mol |
| Liquescens punctum | >207℃(dec.) |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Categoria | API (Active Pharmaceutical Ingredient) |
| Brand | Ruifu Chemical |
| Items | Specifications | Proventus |
| Aspectus | Off-White ad lux Yellow pulveris | Obsequitur |
| Aquae Caroli Fischer | <0.50% | 0.37% |
| Residere in Ignition | <0.20% | 0.09% |
| una immunditia | <0.20% | 0.08% |
| Totalis immunditias | <1.00% | 0.31% |
| Metalla gravis | ≤20ppm | <20ppm |
| Puritas / Analysis Methodus | >99.0% (HPLC) | 99.69% |
| Infrared Imaginis | Congruunt Structure | Obsequitur |
| 1H NMR Imaginum | Congruunt Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
| Fasciae vita | XXIV menses si proprie Repono | |
Sarcina:Utrem, 1kg / 5kg / Aluminium stagni, 25kg / Cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in loco frigido, sicco (2~8℃) reponunt et a cellis bene ventilatis ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Daclatasvir Dihydrochloride (CAS: 1009119-65-6) est hepatitis C virus nonstructurale 5A (NS5A) replicatio complexi inhibitoris quae in Iaponia primum probata est pro curatione genotypi 1 HCV aegros qui plus ribavirin interferoni respondent.Medicamentum etiam probatum est patientibus increatis, chronicis HCV qui habiles sunt ad interferonem.Accedit in Europa, daclatasvir probatus est usui in compositione cum aliis productis per genotypum 1-4 HCV.
Daclatasvir Dihydrochloride est forma salis dihydrochloridis Daclatasviri, viva voce inhibitoris viri hepatitis C (HCV) non-structuralis dapibus 5A (NS5A) replicationis complexi, cum actione potentiali contra HCV.Daclatasvir cum alio medicamento antivirali (Sofosbuvir) adhibetur ut hepatitis C, infectio viralis hepatitis chronica (diuturna) tractaret.Daclatasvir numquam adhiberi debet sine Sofosbuvir.Daclatasvir et Sofosbuvir etiam alio medicamento antivirali adhiberi possunt (Ribavirin).
